Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Aptamer reports success in ongoing work with Unilever
(Sharecast News) - Aptamer Group, a developer of novel 'Optimer' binders for the life sciences industry, updated the market on its ongoing partnership with Unilever on Monday, aimed at creating Optimer binders for use in cosmetic applications. The AIM-traded firm said the collaboration, launched in 2022, was focussed on developing Optimer binders to treat malodour in personal care products.
It said the binders had undergone extensive testing at both Aptamer Group and Unilever, yielding highly positive and reproducible results, suggesting strong potential for incorporation into downstream products.
In light of the successful tests, Aptamer filed a patent on 28 March to protect the developed Optimer binders, securing the company's intellectual property rights.
Currently, testing of the Optimer binders is continuing in Unilever's laboratories, with plans to begin on-person functionality studies in the second half of 2024.
The global deodorant market, valued at $25.6bn in 2023, represented a significant opportunity, with Unilever being the largest antiperspirant and deodorant manufacturer worldwide.
Aptamer said the project was expected to finish within the next two years.
If the trials were successful, it could lead to Aptamer licensing the Optimer binders to Unilever.
"The early success we have seen to date in evaluating our Optimers that aim to treat malodour has been promising," said chief technical officer Dr Arron Tolley.
"We are excited to support our partners at Unilever in advancing these binders to the next stage of development with on-person functionality studies.
"Fast-moving consumer goods (FMCG) like personal care products can progress to market more rapidly than diagnostics or therapeutic products."
Dr Tolley said Optimers offered advantages such as stability, shelf life and consistent manufacturability making them ideal molecules for FMCG and cosmetic applications.
"If the Optimer binders continue to progress through the testing and manufacturing stages in Unilever's hands, then we anticipate the completion of this project within two years."
At 1341 BST, shares in Aptamer Group were up 8.12% at 0.73p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
